Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.
There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consor...
Main Authors: | John K Thuita, Kristina K Wolf, Grace A Murilla, Qiang Liu, James N Mutuku, Yao Chen, Arlene S Bridges, Raymond E Mdachi, Mohamed A Ismail, Shelley Ching, David W Boykin, James Edwin Hall, Richard R Tidwell, Mary F Paine, Reto Brun, Michael Zhuo Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3674995?pdf=render |
Similar Items
-
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.
by: John K Thuita, et al.
Published: (2015-02-01) -
Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis.
by: John K Thuita, et al.
Published: (2012-01-01) -
Trypanosoma brucei rhodesiense transmitted by a single tsetse fly bite in vervet monkeys as a model of human African trypanosomiasis.
by: John K Thuita, et al.
Published: (2008-01-01) -
Development of a safer laboratory vervet monkey model for the study of human African trypanosomiasis
by: Maxwell Waema, et al.
Published: (2014-10-01) -
Anatomic brain asymmetry in vervet monkeys.
by: Scott C Fears, et al.
Published: (2011-01-01)